MacroGenics (NASDAQ:MGNX) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Thursday.
Several other brokerages also recently commented on MGNX. BidaskClub upgraded MacroGenics from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 25th. Citigroup boosted their price objective on MacroGenics from $18.00 to $22.00 and gave the company a “neutral” rating in a research report on Friday, November 10th. BTIG Research reiterated a “buy” rating and issued a $28.00 target price on shares of MacroGenics in a research report on Tuesday, January 23rd. Raymond James Financial reiterated a “buy” rating on shares of MacroGenics in a research report on Monday, December 11th. Finally, Zacks Investment Research downgraded MacroGenics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $30.60.
Shares of MacroGenics (MGNX) traded up $1.94 during trading on Thursday, hitting $27.03. The stock had a trading volume of 497,405 shares, compared to its average volume of 235,673. MacroGenics has a fifty-two week low of $14.36 and a fifty-two week high of $27.07. The stock has a market capitalization of $883.10, a P/E ratio of -38.61 and a beta of 2.80.
Hedge funds have recently modified their holdings of the business. Parametric Portfolio Associates LLC purchased a new stake in MacroGenics during the second quarter valued at approximately $203,000. Teacher Retirement System of Texas purchased a new stake in MacroGenics during the fourth quarter valued at approximately $225,000. MetLife Investment Advisors LLC purchased a new stake in MacroGenics during the fourth quarter valued at approximately $281,000. Private Capital Advisors Inc. purchased a new stake in MacroGenics during the fourth quarter valued at approximately $332,000. Finally, Virtus Fund Advisers LLC purchased a new stake in MacroGenics during the fourth quarter valued at approximately $343,000. Institutional investors and hedge funds own 85.30% of the company’s stock.
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.